Mobile Health in Structural Heart Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions
Rheumatic Heart DiseaseHeart Diseases
Interventions
DEVICE

mHealth

After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.

OTHER

Standard-Care

After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.

All Listed Sponsors
lead

Sri Sathya Sai Institute of Higher Medical Sciences

OTHER

NCT02881398 - Mobile Health in Structural Heart Disease | Biotech Hunter | Biotech Hunter